XATRAL LP 10 mg, extended-release tablet 30 tablets
Active ingredients: Alfuzosin hydrochloride
Commercialized according to BDPMDispensing in France: Prescription only
Extended-release tablet30 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- XATRAL LP 10 mg, comprimé à libération prolongée
- Pharmaceutical form
- comprimé à libération prolongée
- Route of administration
- orale
- Presentation description
- plaquette(s) thermoformée(s) de 30 comprimé(s)
- Marketing authorisation holder
- DIFARMED (ESPAGNE)
- Reimbursement according to BDPM
- 30%
- Reimbursement conditions
- Ce médicament peut être pris en charge ou remboursé par l'Assurance Maladie dans les cas suivants :<br><br>- Troubles liés à une hypertrophie bénigne de la prostate<br>- Troubles urinaires chez les patients atteints de sclérose en plaques (prise en charge sur facture en dehors du périmètre des biens et services remboursables) ; JOURNAL OFFICIEL ; 06/04/11
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 8 Oct 2013
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
61889938CIP74901289CIP133400949012893Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| CHLORHYDRATE D'ALFUZOSINEcomprimé | 10 mg · un comprimé | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.